BidaskClub upgraded shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from a hold rating to a buy rating in a report published on Saturday, September 29th.
Several other analysts also recently commented on ALXN. ValuEngine downgraded Alexion Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, June 26th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a hold rating to a buy rating and set a $140.00 price target on the stock in a research note on Tuesday, June 26th. Citigroup raised their price target on Alexion Pharmaceuticals from $173.00 to $195.00 and gave the stock a buy rating in a research note on Tuesday, September 25th. Jefferies Financial Group restated a hold rating and issued a $123.00 price target on shares of Alexion Pharmaceuticals in a research note on Friday, July 27th. Finally, Stifel Nicolaus raised their target price on Alexion Pharmaceuticals from $130.00 to $136.00 and gave the stock a hold rating in a report on Tuesday, September 25th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the stock. Alexion Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $160.74.
Shares of Alexion Pharmaceuticals stock traded up $2.63 during midday trading on Friday, hitting $121.94. The company had a trading volume of 1,776,401 shares, compared to its average volume of 1,766,533. The company has a quick ratio of 2.27, a current ratio of 2.72 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $30.98 billion, a P/E ratio of 23.63, a PEG ratio of 1.27 and a beta of 0.79. Alexion Pharmaceuticals has a 52-week low of $102.10 and a 52-week high of $144.91.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.49 by $0.58. Alexion Pharmaceuticals had a positive return on equity of 15.21% and a negative net margin of 2.68%. The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $976.81 million. During the same period last year, the business posted $1.56 EPS. The company’s revenue was up 14.5% compared to the same quarter last year. As a group, equities analysts expect that Alexion Pharmaceuticals will post 6.45 EPS for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Brown Advisory Inc. grew its position in Alexion Pharmaceuticals by 297.9% in the second quarter. Brown Advisory Inc. now owns 20,261 shares of the biopharmaceutical company’s stock worth $2,516,000 after acquiring an additional 15,169 shares in the last quarter. Bain Capital Public Equity Management LLC boosted its position in shares of Alexion Pharmaceuticals by 23.2% during the second quarter. Bain Capital Public Equity Management LLC now owns 70,753 shares of the biopharmaceutical company’s stock valued at $8,784,000 after buying an additional 13,318 shares during the period. Essex Financial Services Inc. purchased a new position in shares of Alexion Pharmaceuticals during the second quarter valued at approximately $232,000. Tyers Asset Management LLC boosted its position in shares of Alexion Pharmaceuticals by 15.5% during the second quarter. Tyers Asset Management LLC now owns 6,050 shares of the biopharmaceutical company’s stock valued at $751,000 after buying an additional 814 shares during the period. Finally, CIBC Asset Management Inc boosted its position in shares of Alexion Pharmaceuticals by 2.0% during the second quarter. CIBC Asset Management Inc now owns 55,003 shares of the biopharmaceutical company’s stock valued at $6,829,000 after buying an additional 1,091 shares during the period. Institutional investors own 93.06% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Further Reading: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.